Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (ACET)
NASDAQ:ACET
ACET Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.74 - $2.43
Previous CloseN/A
Volume197.46K
Average Volume (3M)434.75K
Market Cap
$74.11M
Enterprise Value-$53.05M
Total Cash (Recent Filing)$56.49M
Total Debt (Recent Filing)$17.23M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 20, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding82,685,750
10 Day Avg. Volume309,846
30 Day Avg. Volume434,753
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)87.13
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.48
Forecast
1Y Price Target
$6.00Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Adicet Bio News
See All ACET News
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAdicet's ADI-270 demonstrated strong anti-tumor activity and a lower inflammatory profile in trials.
Financial StabilityAdicet highlights a solid cash position of $176.3MM, indicating financial stability.
Regulatory MilestonesADI-001 has been granted FDA Fast Track Designation for the potential treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement, adult patients with systemic sclerosis (SSC), and patients with relapsed or refractory class III or class IV lupus nephritis (LN).
Bears Say
Market ValuationShares trade at about 44% of ending 4Q24 cash, which is seen as a fair discount due to uncertainties.
Operational RisksRisks include commercial, regulatory, development, manufacturing, financial, and liability.
Revenue GenerationFor 4Q24, Adicet reported no revenues, aligning with expectations but still a negative indicator.
---
Ownership Overview
15.64% Insiders
6.29% Mutual Funds
47.34% Other Institutional Investors
26.31% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACET FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was $0.74 and its highest was $2.43 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is $74.11M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is May 20, 2025 which is in 53 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Mar 06, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.357 by $0.037.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -0.33.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 82,685,750 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.357. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in ACET
---
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (566.67% Upside)
$6.00 (566.67% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 21.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.00%
12-Months-Change
Fundamentals
Return on Equity
-65.65%
Trailing 12-Months
Asset Growth
6.23%
Trailing 12-Months
Company Description
Adicet Bio
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
---
ACET Stock 12 Month Forecast
Average Price Target
$6.00
▲(566.67% Upside)
Technical Analysis
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering ACET
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-9.49%
reiterated a buy rating 15 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -9.49% per trade.
---